Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.' - 2As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks
- 3Pick Your Number one breakfast food
- 4Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- 5The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Becoming amazing at Arranging Pay Raises
- Track down the Ideal Weight reduction Methodology for Your Way of life
- Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- Australians told to continue Easter travel plans despite fuel shortages
- Independence from the rat race for Recent college grads: Systems and Tips
- 21 Things You Ought to Never Tell Your Childless Companion
- How to watch 'A Charlie Brown Christmas' for free in 2025
- Brazil's agricultural research agency gets cannabis research greenlight
- The Solution to Flexibility: Developing Internal Fortitude Notwithstanding Misfortune
